Viridian's veligrotug meets all primary & secondary endpoints in Phase 3 THRIVE-2 chronic TED trial

Viridian Therapeutics, Inc.\DE

Proptosis responder rate 56% vs 8% placebo (48% adj, p<0.0001); 2.34mm mean reduction vs 0.46mm.
Diplopia response 56% vs 25% (p=0.0006); complete resolution 32% vs 14% (p=0.0152) in chronic patients.
54% of veligrotug patients achieved CAS 0 or 1 vs 24% placebo (p=0.006); overall responder rate 56% vs 7%.
Veligrotug well-tolerated; 94% completed treatment; 9.6% placebo-adjusted rate of hearing impairment.
BLA submission on track for H2 2025; $753M cash on hand provides runway into H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.